{
  "variants": [
    {
      "name": "D30K",
      "protein_change": "Aspartic acid to lysine at position 30",
      "functional_evidence": "Reduced secretion compared to wild-type UCH-L1",
      "disease_relevance": "Associated with impaired UCH-L1 secretion, linked to Parkinson's disease",
      "acmg_steps": [
        {
          "step": 1,
          "description": "Disease mechanism defined by UCH-L1 secretion in Parkinson's. D30K variant reduces secretion, directly impacting the mechanism.",
          "outcome": "Satisfied"
        },
        {
          "step": 2,
          "description": "Assay (secretion analysis) is applicable to the disease mechanism (secretion in UCH-L1).",
          "outcome": "Satisfied"
        },
        {
          "step": 3,
          "description": "Controls (wild-type) and replicates (cultured cell experiments) are present. Variant control (D30K) is used.",
          "outcome": "Satisfied"
        },
        {
          "step": 4,
          "description": "No statistical analysis (p-values, etc.), but direct comparison shows reduced secretion. Evidence is supportive.",
          "outcome": "PS3_supporting"
        }
      ]
    },
    {
      "name": "C90S",
      "protein_change": "Cysteine to serine at position 90",
      "functional_evidence": "No reduction in secretion compared to wild-type UCH-L1",
      "disease_relevance": "Lacks hydrolase activity but maintains secretion, suggesting non-pathogenic effect on PD mechanism",
      "acmg_steps": [
        {
          "step": 1,
          "description": "Disease mechanism defined by UCH-L1 secretion in Parkinson's. C90S variant maintains secretion, consistent with non-pathogenic role.",
          "outcome": "Satisfied"
        },
        {
          "step": 2,
          "description": "Assay (secretion analysis) is applicable to the disease mechanism (secretion in UCH-L1).",
          "outcome": "Satisfied"
        },
        {
          "step": 3,
          "description": "Controls (wild-type) and replicates (cultured cell experiments) are present. Variant control (C90S) is used.",
          "outcome": "Satisfied"
        },
        {
          "step": 4,
          "description": "No statistical analysis (p-values, etc.), but direct comparison shows normal secretion. Evidence is supportive.",
          "outcome": "BS3_supporting"
        }
      ]
    },
    {
      "name": "I93M",
      "protein_change": "Isoleucine to methionine at position 93",
      "functional_evidence": "Reduced secretion compared to wild-type UCH-L1",
      "disease_relevance": "Linked to Parkinson's disease via impaired UCH-L1 secretion",
      "acmg_steps": [
        {
          "step": 1,
          "description": "Disease mechanism defined by UCH-L1 secretion in Parkinson's. I93M variant reduces secretion, directly impacting the mechanism.",
          "outcome": "Satisfied"
        },
        {
          "step": 2,
          "description": "Assay (secretion analysis) is applicable to the disease mechanism (secretion in UCH-L1).",
          "outcome": "Satisfied"
        },
        {
          "step": 3,
          "description": "Controls (wild-type) and replicates (cultured cell experiments) are present. Variant control (I93M) is used.",
          "outcome": "Satisfied"
        },
        {
          "step": 4,
          "description": "No statistical analysis (p-values, etc.), but direct comparison shows reduced secretion. Evidence is supportive.",
          "outcome": "PS3_supporting"
        }
      ]
    }
  ]
}